Sam Brusco, Associate Editor12.06.23
Kaneka Corporation announced it has acquired all shares of Japan Medical Device Technology (JMDT), a developer of coronary stents and leader in development of bioresorbable stents.
Kaneka makes and sells endovascular catheters, which are used in treatment of cardiac, peripheral vascular, and cerebrovascular diseases. The company said stenting to treat coronary artery diseases like atherosclerosis is a ¥300 billion market in Japan.
JMDT has high technological capabilities in research and development of coronary stents. JMDT's bioresorbable stent is made of a biodegradable magnesium alloy, which prevents vessel blockage potentially caused by the stent remaining in the vessel. has a low risk of thrombosis with a thin (100 µm) yet fully expandable stent body. Its surface is coated with a layer that controls the degradation of the magnesium alloy and drug (Sirolimus) elution.
In addition, 95% of the stent is resorbed and taken up by the body 1.5 years after implantation, ensuring that it does not interfere with the treatment of restenosis. it is currently the only bioresorbable stent in Japan that has progressed to the first-in-human trial for use in humans for the first time.
Kaneka is headquartered in Minato-ku, Tokyo. Its president is Minoru Tanaka. JMDT is headquartered in Kamimashiki-gun, Kumamoto and its president is Shuzo Yamashita.
Kaneka makes and sells endovascular catheters, which are used in treatment of cardiac, peripheral vascular, and cerebrovascular diseases. The company said stenting to treat coronary artery diseases like atherosclerosis is a ¥300 billion market in Japan.
JMDT has high technological capabilities in research and development of coronary stents. JMDT's bioresorbable stent is made of a biodegradable magnesium alloy, which prevents vessel blockage potentially caused by the stent remaining in the vessel. has a low risk of thrombosis with a thin (100 µm) yet fully expandable stent body. Its surface is coated with a layer that controls the degradation of the magnesium alloy and drug (Sirolimus) elution.
In addition, 95% of the stent is resorbed and taken up by the body 1.5 years after implantation, ensuring that it does not interfere with the treatment of restenosis. it is currently the only bioresorbable stent in Japan that has progressed to the first-in-human trial for use in humans for the first time.
Kaneka is headquartered in Minato-ku, Tokyo. Its president is Minoru Tanaka. JMDT is headquartered in Kamimashiki-gun, Kumamoto and its president is Shuzo Yamashita.